Active Platelet Factor 4 (PF4) Mus musculus (Mouse) Active protein

CXCL4; SCYB4; Chemokine C-X-C-Motif Ligand 4; Oncostatin-A; Iroplact

Add to Cart Distributors
Overview
Properties
  • Buffer Formulation20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder, Purity > 90%
  • Isoelectric Point9.4
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Platelet Factor 4 (PF4) Packages (Simulation)
  • Active Platelet Factor 4 (PF4) Packages (Simulation)
  • APA172Mu01.png Figure. SDS-PAGE
  • Active Platelet Factor 4 (PF4) Sample: Recombinant PF4, Mouse;
    Antibody: Rabbit Anti-Mouse PF4 Ab (PAA172Mu01)
    Figure. Western Blot
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Platelet factor 4 (PF4) is a small cytokine belonging to the CXC chemokine family that is also known as chemokine (C-X-C motif) ligand 4 (CXCL4). This chemokine is released from alpha-granules of activated platelets during platelet aggregation, and promotes blood coagulation by moderating the effects of heparin-like molecules. Due to these roles, it is predicted to play a role in wound repair and inflammation. To measure its ability to inhibit the FGF basic-dependent proliferation of HUVEC human umbilical vein endothelial cells, HUVEC cells were seeded into 96-well plates at a density of 3,000 cells/well with 2% serum standard DMEM including 1μg/mL recombinant human FGF1 and various concentrations of recombinant human PF4. After incubated for 48h, cells were observed by inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10µL of CCK-8 solution was added to each well of the plate, then the absorbance at 450nm was measured using a microplate reader after incubating the plate for 1-2 hours at 37℃. Proliferation of HUVEC cells after incubation with PF4 for 48h observed by inverted microscope was shown in Figure 1. Cell viability was assessed by CCK-8 (Cell Counting Kit-8) assay after incubation with recombinant human PF4 for 48h. The result was shown in Figure 2. It was obvious that PF4 significantly FGF basic-dependent proliferation of HUVEC cells. The ED50 is 3.4μg/mL.
(A)HUVEC cells cultured in DMEM with 1μg/mL FGF1, stimulated with 5μg/mL PF4 for 48h;
(B) Unstimulated HUVEC cells cultured in DMEM with 1μg/mL FGF1 for 48h.
Figure. Inhibition of HUVEC cells proliferation after stimulated with PF4.

Figure. Inhibition of FGF basic-dependent HUVEC proliferation after stimulated with PF4.

Usage

Reconstitute in 20mM Tris, 150mM NaCl (PH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic ratsPubMed: 20601223
  • Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilationPubMed: 22899170
  • Platelets Recognize Brain-Specific Glycolipid Structures, Respond to Neurovascular Damage and Promote NeuroinflammationPubMed: PMC3608633
  • Effect of splenectomy on platelet activation and decompression sickness outcome in a rat model of decompressionPubmed:25311322
  • A Phellinus baumii–based supplement containing Salvia miltiorrhiza Bunge improves atherothrombotic profiles through endothelial nitric oxide synthase and cyclooxygenase pathwaysin vitro and in vivoscience:S1756464616300676
  • Aspirin, but Not Tirofiban Displays Protective Effects in Endotoxin Induced Lung Injurypubmed:27583400
  • Evidence of the Role of R-Spondin 1 and Its Receptor Lgr4 in the Transmission of Mechanical Stimuli to Biological Signals for Bone Formation.pubmed:28272338
  • Feasibility of improving platelet‑rich plasma therapy by using chitosan with high platelet activation abilitypubmed:28450960
  • Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in ratsPubmed: 30528429
  • Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablationPubmed: 30857843
  • Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers
  • Newly Identified HNP‐F from Human Neutrophil Peptide 1 Promotes HemostasisPubmed: 30927490
  • Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation
  • Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular MarkersPubmed: 32812629
  • The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in RodentsPubmed: 31533230
  • Feasibility study of use of rabbit blood to evaluate platelet activation by medical devicesPubmed: 31838449
  • The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets34099640
  • The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female ratsPubmed:35183388

Recommend products